CFL1 and hepatocellular carcinoma: Systemic co‐delivery of sorafenib and siCFL1 by reduction‐responsive NPs could effectively silence CFL1 expression and enhance sorafenib sensitivity in vivo, thereby leading to a significant inhibition of HCC tumor growth.